- Home
- IRD vs VTVT Comparison
IRD vs VTVT Comparison
Compare IRD & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- VTVT
- Stock Information
- Founded
- IRD 2018
- VTVT 2015
- Country
- IRD United States
- VTVT United States
- Employees
- IRD N/A
- VTVT N/A
- Industry
- IRD
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- IRD
- VTVT Health Care
- Exchange
- IRD NYSE
- VTVT Nasdaq
- Market Cap
- IRD 62.0M
- VTVT 56.7M
- IPO Year
- IRD N/A
- VTVT 2015
- Fundamental
- Price
- IRD $0.95
- VTVT $15.55
- Analyst Decision
- IRD Strong Buy
- VTVT Strong Buy
- Analyst Count
- IRD 3
- VTVT 2
- Target Price
- IRD $6.33
- VTVT $35.50
- AVG Volume (30 Days)
- IRD 2.4M
- VTVT 3.2K
- Earning Date
- IRD 08-15-2025
- VTVT 08-07-2025
- Dividend Yield
- IRD N/A
- VTVT N/A
- EPS Growth
- IRD N/A
- VTVT N/A
- EPS
- IRD N/A
- VTVT N/A
- Revenue
- IRD $13,651,000.00
- VTVT $17,000.00
- Revenue This Year
- IRD $51.41
- VTVT N/A
- Revenue Next Year
- IRD $68.84
- VTVT N/A
- P/E Ratio
- IRD N/A
- VTVT N/A
- Revenue Growth
- IRD N/A
- VTVT N/A
- 52 Week Low
- IRD $0.65
- VTVT $12.12
- 52 Week High
- IRD $2.18
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- VTVT 37.38
- Support Level
- IRD N/A
- VTVT $15.17
- Resistance Level
- IRD N/A
- VTVT $16.61
- Average True Range (ATR)
- IRD 0.00
- VTVT 0.35
- MACD
- IRD 0.00
- VTVT 0.00
- Stochastic Oscillator
- IRD 0.00
- VTVT 24.58
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.